Organization (Nonprofit)
Groupe Francophone des Myélodysplasies
ClinicalTrials.gov lists Groupe Francophone des Myélodysplasies as lead sponsor of 43 trials. It has 13 active development programs and 17 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Groupe Francophone des Myélodysplasies: 43 lead-sponsored trials and 1 legal-entity registration.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Myelodysplastic Syndromes | 29 |
| Leukemia, Myeloid, Acute | 11 |
| Anemia | 5 |
| Leukemia, Myelomonocytic, Chronic | 4 |
| Anemia, Refractory, with Excess of Blasts | 2 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 2 |
Showing 10 of 19 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 28 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (13)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| EPREX | Myelodysplastic Syndromes | Phase 3 | 2 |
| AG-221 | Myelodysplastic Syndromes | Phase 2 | 1 |
| AG-221 | Leukemia, Myeloid, Acute | Phase 2 | 1 |
| Momelotinib treatment | Myelodysplastic Syndromes | Phase 2 | 1 |
| AG-120 | Myelodysplastic Syndromes | Phase 2 | 1 |
Showing 5 of 13 active programs.
Approved assets (17)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Decitabine | 2 |
| EPREX | 2 |
| HYDROXYUREA | 1 |
| AZACITIDINE (VIDAZA) | 6 |
| EPOETIN ALFA | 3 |
Showing 5 of 17 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=12) | 36% on time (n=14) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 8 |
| Haematologica | 4 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 4 |
| Leukemia | 4 |
| The Lancet. Haematology | 3 |
Showing 5 of 13 journals.
Organization relationships (18)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Bristol Myers Squibb Co | Co sponsors trial with | 6 |
| Australasian Leukaemia and Lymphoma Group | Co sponsors trial with | 1 |
| Genzyme, a Sanofi Company | Co sponsors trial with | 1 |
| GCP-Service International West GmbH | Co sponsors trial with | 1 |
| Centre National de la Recherche Scientifique | Co sponsors trial with | 1 |
Showing 5 of 18 relationships.
Latest dated events (47)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-12-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-06-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 47 events.
Biomarker capability evidence (194)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ASXL1 | Trial sponsor | Named in trial inclusion criteria |
| CCR7 | Trial sponsor | Named in trial inclusion criteria |
| CCR7 | Trial sponsor | Named in trial inclusion criteria |
| CPOX | Trial sponsor | Named in trial inclusion criteria |
| CSF1R | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 194 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.